Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

Completed · Phase 2

Conditions studied: Glioblastoma

In brief

This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.

Key facts

Study ID

NCT02014844

Run by

ImmunityBio, Inc.

People needed

28

Starts

2014-03-01

Expected to finish

2016-12-01

Last updated by the study team

2024-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older; male or female
• Histologically or cytologically confirmed unresectable GBM. Subjects with recurrent disease whose prior pathology demonstrated GBM will not need to be re-biopsied. Subjects with prior low-grade glioma or anaplastic glioma are eligible if histological assessment demonstrates transformation into GBM.
• Cancer progression after treatment with the following: surgery, radiation therapy and temozolomide as first line treatment with no other therapy prior to tumor recurrence.
• Radiographic progression by RANO Working Group Criteria will be confirmed by Imaging Endpoints, a central imaging vendor.
• By tumor biopsy if conducted within 4 weeks of randomization.
• An interval of at least 12 weeks after last dose of radiation and temozolomide is required, unless cancer progression is proven by diagnostic tumor biopsy. If temozolomide is being used in a maintenance phase, there must be a 28-day washout period prior to Randomization.
• Stable or decreasing dose of corticosteroids for at least 7 days prior to randomization.
• Capable of providing informed consent and complying with trial procedures.
• Karnofsky Performance Status 70 or above.
• ECOG performance status 0-2.
• Life expectancy 8 or more weeks.
• Measurable tumor lesions according to RANO working Group Criteria.
• a. In the case that there is "non-measurable" disease due to a radical surgical resection during screening, the subject still qualifies if Inclusion #3(b) is met.
• Women must not be able to become pregnant for the duration of the study.
• Women of childbearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
• Geographically accessible to site, i.e. the ability to come to the study site for each scheduled appointment and evaluation.

You may not qualify if…

• Prior exposure to the an anthracycline.
• Any therapeutic regimen for treatment of recurrent tumor after first line treatment with surgery, radiation and temozolomide.
• Prior treatment with bevacizumab or an experimental anti-angiogenic agent.
• Palliative surgery and/or radiation treatment less than 4 weeks to randomization.
• Exposure to any investigational agent within 30 days of Randomization.
• History of other malignancies (except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix) unless documented free of cancer for 3 or more years.
• Laboratory values: screening serum creatinine > 1.5xULN, ALT > 2.5xULN, total bilirubin > 1.5xULN, ANC < 1500/mm3, platelet concentrations < 100,000/mm3, absolute lymphocyte count < 1000/mm3, hematocrit level < 27% for females or < 30% for males, serum albumin ≤ 2.5 g/dL, PT/INR 1.5xULN or >3xULN on anticoagulant with no evidence of active bleeding.
• Evidence of CNS hemorrhage CTCAE ≥ grade 2 on baseline MRI.
• Clinically evident congestive heart failure > class II of the NYHA guidelines.
• Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrythmias classified as Lown III, IV or V.
• History or signs of active coronary artery disease with or without angina pectoris.
• Serious myocardial dysfunction defined as ultrasound-determined LVEF < 45% of predicted institutional normal value.
• Baseline ATc>470 msec and/or previous history of QT prolongation.
• Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals, or anti-fungals.
• History of HIV infection.
• Major surgery, except diagnostic tumor biopsy, within 4 weeks of randomization.
• Any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.
• Any condition that is unstable and could jeopardize the subject's participation in the study.

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• Sarcoma Oncology Center — Santa Monica, California, United States
• Ochsner Health System — New Orleans, Louisiana, United States
• Texas Oncology-Austin Midtown — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.